2022-06-07 | TSX:ASP | Press release

TORONTO, June 07, 2022 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (the “Company” Where “Polled”) (TSX: ASP; OTCQB: ASPCD) today announced that it has entered into an Amended and Restated Promissory Note (the “Note A&R”) covering initial fees owed to the former Serenity Pharmaceuticals LLC (“Serenity”) securityholders. Under the original promissory note, the initial fee, less deductions, in the amount of US$4.91 million was to be paid on June 7, 2022. The securityholders’ representative and Acerus have agreed to postpone the date A&R note maturity date of July 8, 2022 to give Acerus more time to secure additional funding.

About Acerus

Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that enhance the patient experience, with a particular focus on the area of ​​men’s health. The Company markets its products through its own sales force in the United States and Canada, and through a worldwide network of authorized distributors in other territories.

Acerus’ the shares trade on the TSX under the symbol ASP and on the OTCQB under the symbol ASPCD. For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.

Notice Regarding Forward-Looking Statements

Information contained in this press release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. This information implicitly contains assumptions regarding our future operating results. These assumptions, although considered reasonable by the company at the time of their preparation, may prove to be incorrect. Readers are cautioned that the actual performance of the Company is subject to a number of risks and uncertainties, including with respect to the commercial performance of NATESTO® and NOCTIVA® globally and in the United States as well as the Company’s ability to obtain financing to pay the A&R rating at maturity and execute its strategy, and could differ materially from what is currently expected as indicated above. For more comprehensive information on these risks and uncertainties, you should refer to our annual information form dated March 14, 2022 available at www.sedar.com. The forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe to be reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely on such information as of any other date. Although we may choose to do so, we are under no obligation and do not undertake to update this information at any time, whether as a result of new information, future events or otherwise, unless applicable securities law requires it.

Company details

ir@aceruspharma.com

Investor Relations

chris witty

Acerus Investor Relations

(646) 438-9385

cwitty@darrowir.com

main logo

Comments are closed.